AKT1 and nonpapillary renal cell carcinoma: Based on our findings, we propose that in ccRCC, which typically harbors inactivating SETD2 mutations, the PI3Kβ-AKT axis is essential for growth and migration and that when targeted, is inhibitory to cells with SETD2 loss, therefore revealing tantalizing therapeutic applications.